
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
ACIP Votes to End Universal Hepatitis B Vaccination Recommendation for Infants
3
American Cancer Society Updates Cervical Cancer Screening Guidelines to Include Self-Collection for HPV Testing
4
Unit-Based Pharmacy: Advancing Practice for Tomorrow
5

















































































































































































































